VEGFA and renal cell carcinoma: In recent years, progress has been made in the treatment of RCC patients with advanced disease, to a large extent due to the introduction of anti‐angiogenic drugs targeting the VEGF pathway, including the kinase inhibitors sunitinib, pazopanib, axitinib, and cabozantinib 4, 13 and the anti‐VEGF antibody bevacizumab (in combination with interferon) 14.